Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHENNONG real-world study of evolocumab plus standard therapy versus standard therapy alone in Chinese patients with atherosclerotic cardiovascular disease
CTR20192138Phase 4Active
- Sponsor
- Amgen
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab, sponsored by Amgen. Started Dec 2022; status: active.
02
Drugs
evolocumab
Beyond the preview
Go deeper on CTR20192138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192138.